Page last updated: 2024-10-24

anterograde dendritic transport of neurotransmitter receptor complex

Definition

Target type: biologicalprocess

The directed movement of a neurotransmitter receptor complex along microtubules in nerve cell dendrites towards the postsynapse. [GOC:dos]

Anterograde dendritic transport of neurotransmitter receptor complexes is a complex process involving multiple cellular components and molecular mechanisms, crucial for establishing and maintaining neuronal communication. This process involves the movement of newly synthesized or recycled neurotransmitter receptors from the cell body to the dendritic spines, where they are incorporated into synapses.

**1. Synthesis and Assembly:**

* Neurotransmitter receptors are synthesized in the endoplasmic reticulum (ER) of the neuronal cell body.
* After synthesis, they undergo folding and assembly, often with accessory proteins, to form functional receptor complexes.

**2. Sorting and Packaging:**

* Once assembled, receptor complexes are sorted and packaged into transport vesicles in the Golgi apparatus.
* These vesicles are coated with specific proteins, like clathrin or adaptor proteins, which facilitate their movement along microtubules.

**3. Motor Protein-Driven Movement:**

* The transport vesicles containing receptor complexes are transported along microtubules by motor proteins, specifically kinesin.
* Kinesin uses ATP hydrolysis to move the vesicle towards the plus end of the microtubule, which is oriented towards the dendrites.

**4. Dendritic Targeting:**

* Receptor complexes are specifically targeted to dendritic spines through a combination of signals:
* **Zip codes:** Specific sequences within the receptor protein or associated adaptor proteins may act as zip codes, directing them to specific dendritic regions.
* **Signal transduction pathways:** Activation of specific signaling pathways in the dendrite can influence the trafficking of receptors.

**5. Insertion into Synapses:**

* Upon reaching the dendritic spine, the transport vesicles fuse with the plasma membrane, releasing the receptor complex into the synapse.
* The receptors are then incorporated into the postsynaptic density (PSD), a specialized structure that contains other signaling molecules, contributing to synaptic plasticity.

**6. Recycling and Degradation:**

* Neurotransmitter receptors can be recycled back to the cell body through retrograde transport via dynein, another motor protein.
* Alternatively, they can be degraded in lysosomes, a cellular organelle responsible for breaking down cellular components.

**The anterograde dendritic transport of neurotransmitter receptor complexes is essential for:**

* **Synaptic plasticity:** The dynamic regulation of receptor trafficking allows for adjustments in synaptic strength and efficiency in response to neuronal activity.
* **Development and maturation of synapses:** Proper transport of receptors is crucial for the formation and stabilization of functional synapses.
* **Learning and memory:** Changes in receptor density at synapses are implicated in learning and memory processes.

**Disruptions in this process can contribute to:**

* **Neurological disorders:** Dysregulation of receptor trafficking has been linked to a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and autism spectrum disorder.
* **Cognitive impairments:** Deficits in synaptic plasticity and signaling can lead to cognitive impairments, such as learning and memory problems.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Kinesin-1 heavy chainA kinesin-1 heavy chain that is encoded in the genome of human. [PRO:DNx, UniProtKB:P33176]Homo sapiens (human)

Compounds (5)

CompoundDefinitionClassesRoles
whi p180
staurosporineindolocarbazole alkaloid;
organic heterooctacyclic compound
apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
zd 6474CH 331: structure in first sourcearomatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine
antineoplastic agent;
tyrosine kinase inhibitor
lenvatiniblenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
cabozantinibcabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.

cabozantinib: a multikinase inhibitor
aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor